WASHINGTON, D.C. - (Mealey's) The U.S. Supreme Court on
June 17 ruled 5-3 that reverse-payment settlements of patent litigation between
the holder of a drug patent and potential generic manufacturers of the drug are
not necessarily immunized from an antitrust challenge, even if the
anti-competitive effects of the agreement fall within the scope of the
exclusionary potential of the patent, and that reverse-payment settlements should
be analyzed under the rule of reason (Federal Trade Commission v. Actavis,
Inc., et al., No. 12-416, U.S. Sup.; See March 2013) (lexis.com
subscribers may access Supreme Court briefs and the opinion for this case).
Read the rest of the article at the LexisNexis Patent Law
For more information about LexisNexis
products and solutions connect with us through our corporate site.